Woodline Partners LP Gemini Therapeutics, Inc. Transaction History

Woodline Partners LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.39 - $4.0 $449,269 - $751,916	-187,979 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.3 - $6.32 $494,221 - $946,508	149,764 Added 391.9%	187,979 $759,000
Q2 2021 Aug 16, 2021	SELL	$6.32 - $14.02 $1.9 Million - $4.21 Million	-300,090 Reduced 88.7%	38,215 $247,000
Q1 2021 May 17, 2021	BUY	$11.32 - $18.0 $3.83 Million - $6.09 Million	338,305 New	338,305 $4.58 Million

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.